Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer (LEPRE Trial)

PHASE3RecruitingINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

September 22, 2022

Primary Completion Date

September 22, 2029

Study Completion Date

September 22, 2029

Conditions
Carcinoma, Ovarian EpithelialLow Grade Serous Adenocarcinoma of Ovary
Interventions
DRUG

Letrozole tablets

ATC: L02BG04

DRUG

carboplatin AUC 5 and paclitaxel 175 mg/m2

ATC: L01XA02 and ATC: L01CD01 respectively

Trial Locations (19)

13875

RECRUITING

Ospedale degli Infermi, Ponderano

16128

RECRUITING

Medical Oncology Division, Ente Ospedaliero Ospedali Galliera, Genova

20133

RECRUITING

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

20141

RECRUITING

IEO, Milan

21100

RECRUITING

Ospedale Del Ponte, Varese

22042

RECRUITING

Ospedale Sant'Anna, Como

25124

RECRUITING

Fondazione Poliambulanza, Brescia

31033

RECRUITING

IRCCS Istituto Oncologico Veneto, Castelfranco Veneto

31100

RECRUITING

Ospedale Ca' Foncello, Treviso

32100

RECRUITING

Ospedale San Martino, Belluno

35128

RECRUITING

IRCCS Istituto Oncologico Veneto, Padua

44124

RECRUITING

AOU Ferrara, Ferrara

47014

RECRUITING

IRST, Meldola

52100

RECRUITING

Ospedale San Donato, Arezzo

Unknown

RECRUITING

ASST degli Spedali Civili di Brescia, Brescia

RECRUITING

AUSL Romagna, Rimini

00144

RECRUITING

IFO Regina Elena, Roma

00161

RECRUITING

Policlinico Umberto I, Roma

00168

RECRUITING

Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma

All Listed Sponsors
collaborator

Istituto Di Ricerche Farmacologiche Mario Negri

OTHER

collaborator

Humanitas Hospital, Italy

OTHER

lead

Ente Ospedaliero Ospedali Galliera

OTHER